AIM ImmunoTech announces $2.65M at-market financing under NYSE American rules
What's the deal? AIM ImmunoTechDealroom has a profile for this one. Try Dealroom →, a biopharmaceutical company listed on NYSE American, announced on June 9 that it has entered into definitive agreements for a registered direct offering and concurrent private placement. The deal is priced at-the-market under NYSE American rules and will generate gross proceeds of approximately $2.65 million, before deducting placement agent commissions and other offering expenses.
What could go wrong? At just $2.65 million, this is a modest raise — typical of micro-cap biotechs that may struggle to attract larger institutional backing. Frequent small financings can dilute existing shareholders and signal limited options for capital access.
The signal: Dealroom classifies AIM ImmunoTech as a "mature" company, yet a $2.65 million at-market raise is more characteristic of a survival-stage micro-cap — underscoring how even long-established biotech firms can find themselves reliant on dilutive, small-ticket public offerings when clinical and commercial milestones remain elusive.
Read more: aktiencheck.de
